APGE
Apogee Therapeutics, Inc. NASDAQ Listed Jul 14, 2023$134.11
Mkt Cap $8.3B
52w Low $34.34
99.7% of range
52w High $134.46
50d MA $112.77
200d MA $82.93
P/E (TTM)
—
EV/EBITDA
—
P/B
9.0x
Debt/Equity
0.0x
ROE
-28.3%
P/FCF
-35.0x
RSI (14)
54.70
ATR (14)
$0.27
Beta
1.02
50d MA
$112.77
200d MA
$82.93
Avg Volume
4.4M
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
221 Crescent Street · Waltham, MA 02453 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMC | -1.05 | -1.03 | +1.9% | 70.92 | -3.0% | -3.4% | +5.6% | -1.9% | +3.0% | +2.6% | — |
| Nov 10, 2025 | AMC | -1.12 | -1.11 | +0.9% | 56.77 | -0.1% | +10.9% | +0.2% | -0.2% | +4.0% | -1.0% | — |
| Aug 11, 2025 | AMC | -1.03 | -1.13 | -9.7% | 34.65 | +1.4% | +5.9% | +1.8% | +2.0% | -2.2% | -1.0% | — |
| May 12, 2025 | AMC | -1.19 | -0.95 | +20.2% | 39.58 | +1.2% | +0.4% | +0.3% | +2.0% | -0.0% | -1.7% | — |
| Mar 3, 2025 | AMC | -0.94 | -1.19 | -26.6% | 31.39 | -2.3% | -3.2% | +3.5% | +12.8% | +2.0% | +3.9% | — |
| Nov 12, 2024 | AMC | -0.88 | -0.86 | +2.2% | 57.35 | -0.1% | -8.0% | -3.4% | -7.4% | -4.1% | +2.6% | — |
| Aug 12, 2024 | AMC | -0.64 | -0.60 | +6.2% | 44.46 | -0.7% | -0.1% | -0.4% | +2.4% | -0.1% | +10.6% | — |
| May 13, 2024 | AMC | -0.60 | -0.64 | -6.7% | 52.73 | +1.9% | +2.4% | -1.3% | +0.8% | -6.4% | +4.2% | — |
| Mar 5, 2024 | AMC | -0.45 | -0.32 | +28.9% | 59.30 | +3.0% | +12.5% | -2.2% | +3.5% | -2.0% | +4.7% | — |
| Nov 13, 2023 | AMC | -0.38 | -0.51 | -34.2% | 16.28 | +2.1% | +5.1% | +4.4% | -5.9% | +8.9% | -1.5% | — |
| Jul 17, 2023 | AMC | -1.70 | -3.78 | -122.4% | 20.80 | +0.0% | -0.5% | -1.2% | -0.2% | -0.0% | -0.4% | — |
| Mar 31, 2023 | AMC | — | -0.25 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Rothschild & Co Redburn | Initiates | Buy | $140 | $82.89 | $83.99 | +1.3% | -2.6% | +3.5% | -0.3% | +1.5% | -3.2% |
| Mar 30 | Mizuho | Maintains | Outperform → Outperform | — | $77.82 | $78.04 | +0.3% | +1.2% | +6.9% | +0.1% | +0.1% | -0.4% |
| Mar 24 | Canaccord Genuity | Maintains | Buy → Buy | — | $79.24 | $79.48 | +0.3% | -7.9% | +7.6% | -0.1% | -0.8% | +1.2% |
| Mar 24 | Citigroup | Maintains | Buy → Buy | — | $79.24 | $79.48 | +0.3% | -7.9% | +7.6% | -0.1% | -0.8% | +1.2% |
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $79.24 | $79.48 | +0.3% | -7.9% | +7.6% | -0.1% | -0.8% | +1.2% |
| Mar 23 | BTIG | Maintains | Buy → Buy | — | $66.04 | $77.32 | +17.1% | +20.0% | -7.9% | +7.6% | -0.1% | -0.8% |
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $71.90 | $72.01 | +0.2% | -1.1% | -1.7% | -4.4% | +2.6% | -3.6% |
| Mar 3 | Wedbush | Maintains | Outperform → Outperform | — | $70.92 | $68.78 | -3.0% | -3.4% | +5.6% | -1.9% | +3.0% | +2.6% |
| Mar 3 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $70.92 | $68.78 | -3.0% | -3.4% | +5.6% | -1.9% | +3.0% | +2.6% |
| Jan 22 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $81.91 | $79.98 | -2.4% | -2.5% | -12.3% | +0.0% | +3.4% | -2.3% |
| Jan 6 | BTIG | Maintains | Buy → Buy | — | $77.51 | $75.00 | -3.2% | +1.0% | +0.9% | -1.9% | +0.7% | -0.4% |
| Jan 5 | BTIG | Maintains | Buy → Buy | — | $75.78 | $75.55 | -0.3% | +2.3% | +1.0% | +0.9% | -1.9% | +0.7% |
| Nov 3 | RBC Capital | Maintains | Outperform → Outperform | — | $56.59 | $56.98 | +0.7% | -4.0% | -0.8% | +2.9% | -0.8% | -0.5% |
| Oct 9 | BTIG | Maintains | Buy → Buy | — | $47.24 | $48.42 | +2.5% | +12.6% | -1.4% | +2.9% | -3.0% | +6.6% |
| Aug 28 | BofA Securities | Maintains | Buy → Buy | — | $37.79 | $37.96 | +0.4% | -3.1% | -0.7% | +4.1% | +0.8% | -2.7% |
| Jul 2 | Guggenheim | Maintains | Buy → Buy | — | $44.26 | $44.12 | -0.3% | +0.1% | +7.1% | -17.3% | -7.2% | +1.7% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $39.72 | $39.86 | +0.4% | -0.9% | -12.4% | +2.9% | +2.1% | +0.8% |
| Dec 12 | Guggenheim | Maintains | Buy → Buy | — | $48.77 | $48.77 | +0.0% | -9.1% | +0.4% | +6.1% | +1.9% | -7.1% |
| Dec 3 | Guggenheim | Maintains | Buy → Buy | — | $46.14 | $46.42 | +0.6% | +0.3% | +12.5% | -9.3% | +6.0% | -1.8% |
| Dec 2 | Wedbush | Maintains | Outperform → Outperform | — | $45.15 | $45.75 | +1.3% | +2.2% | +0.3% | +12.5% | -9.3% | +6.0% |
| Nov 27 | Guggenheim | Maintains | Buy → Buy | — | $43.96 | $45.08 | +2.5% | +1.7% | +1.0% | +2.2% | +0.3% | +12.5% |
| Oct 25 | Wedbush | Maintains | Outperform → Outperform | — | $51.95 | $52.45 | +1.0% | +2.5% | +3.2% | +2.6% | -2.5% | -5.2% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $59.30 | $61.08 | +3.0% | +12.5% | -2.2% | +3.5% | -2.0% | +4.7% |
| Mar 5 | Guggenheim | Maintains | Buy → Buy | — | $41.74 | $59.91 | +43.5% | +42.1% | +12.5% | -2.2% | +3.5% | -2.0% |
| Mar 5 | Stifel | Maintains | Buy → Buy | — | $41.74 | $59.91 | +43.5% | +42.1% | +12.5% | -2.2% | +3.5% | -2.0% |
| Jan 3 | Guggenheim | Maintains | Buy → Buy | — | $28.51 | $28.86 | +1.2% | -3.0% | +2.2% | -2.4% | +7.2% | +4.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Dambkowski CarlOff | Chief Medical Officer | Sell | 5,500 | $132.74 | $730K | 177,873 | +0.44% | +0.06% |
| Jun 22, 2026 | HENDERSON MICHAEL THOMASDir/Off | Chief Executive Officer | Sell | 80,000 | $132.54 | $10.6M | 1,015,987 | -0.01% | +0.03% |
| Jun 22, 2026 | Dambkowski CarlOff | Chief Medical Officer | Sell | 26,400 | $132.60 | $3.5M | 179,248 | -0.01% | +0.03% |
| May 1, 2026 | Henderson JaneOff | Chief Financial Officer | Sell | 289 | $83.16 | $24K | 173,371 | -0.31% | +1.89% |
| May 1, 2026 | Henderson JaneOff | Chief Financial Officer | Sell | 900 | $82.60 | $74K | 173,660 | -0.31% | +1.89% |
| May 1, 2026 | Henderson JaneOff | Chief Financial Officer | Sell | 811 | $81.02 | $66K | 174,560 | -0.31% | +1.89% |
8-K · 2.02
!! High
AbbVie Inc. -- 8-K 2.02: Earnings Results
Jul 31
8-K
Apogee Therapeutics, Inc. -- 8-K Filing
Apogee Therapeutics' merger deal proceeds without financing contingencies, with a guarantor backing the acquirer's obligations under the agreement.
Jun 22
8-K
Apogee Therapeutics, Inc. -- 8-K Filing
Apogee Therapeutics faces potential termination of its IL-31R discovery agreement with its partner if research activities are suspended for four consecutive months or if either party materially breaches the contract.
Jun 22
8-K · 8.01
!! High
Apogee Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 27
8-K · 1.01
!! High
Apogee Therapeutics, Inc. -- 8-K 1.01: Material Agreement
May 27
8-K · 2.02
!! High
Apogee Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Apogee Therapeutics disclosed financial results and operational performance in a press release, with full details available in the earnings announcement exhibit attached to the 8-K filing.
May 11
8-K · 5.02
!!! Very High
Apogee Therapeutics, Inc. -- 8-K 5.02: Executive Change
Apogee Therapeutics lost two directors, Andrew Gottesdiener and Peter Harwin, effective May 11, 2026, potentially signaling governance transition or underlying concerns about company direction.
Apr 24
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
APGE entered an underwriting agreement with Jefferies, likely signaling an upcoming equity or debt offering that could dilute shareholders but provides capital for growth or debt management.
Mar 25
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
APGE's positive Phase 2 data for zumilokibart in Alzheimer's disease de-risks the pipeline and could support higher valuations if efficacy/safety profile remains compelling through later-stage trials.
Mar 23
8-K
Apogee Therapeutics, Inc. -- 8-K Filing
Apogee Therapeutics maintains strong cash reserves of $902.9 million extending runway to mid-2028, positioning the company to advance zumilokibart toward a potential 2029 launch while generating interim atopic dermatitis data.
Mar 2
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$8.30B
Enterprise Value
$7.41B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.64x
P/B
9.00x
P/S
—
P/FCF
-34.99x
EV/EBITDA
—
Shares Out
60.7M
Financials (TTM)
Revenue
$0
Net Income
-$274.6M
EBITDA
-$272.7M
Free Cash Flow
-$232.6M
Op Cash Flow
-$227.4M
EPS Basic
$-4.22
EPS Diluted
$-4.33
EPS Forward
$-4.66
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$937.1M
Total Liab.
$33.3M
Total Equity
$903.9M
Cash
$730.2M
LT Debt
$5.3M
Book Value/Sh
$14.89
Debt/Equity
0.01x
Current Ratio
26.57
Quick Ratio
26.57
Returns & Growth
ROE
-28.3%
ROA
-27.3%
ROIC
-31.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
-27.9%
Price Returns
2W
-0.0%
1M
+0.5%
3M
+60.5%
6M
+106.7%
12M
+260.1%
Technicals
52W High
$134.46
52W Low
$34.34
50d MA
$112.77
200d MA
$82.93
RSI (14)
54.70
ATR (14)
$0.27
Beta
1.02
Avg Volume
4.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$105.63
High
$137.00
Low
$83.00
Median
$99.00
Data updated apr 24, 2026 6:26pm
· Source: financialmodelingprep.com